No Data
No Data
Express News | X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30TH Annual Eha Congress
Cantor Fitzgerald Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $14
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $7
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7
X4 Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)